Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 2: Bosentan Extension in Pediatric PAH
NCT00319020Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2005
- Primary completion
- Oct 2011
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change From Baseline to End of Study in Height for Age at 32 months, Change From Baseline to End of Study in Body Weight at 32 months and 6 more. Started Aug 2005; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00319020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319020.